Device-Activated Drugs, An Old Dog With Some New Tricks

Jason Menzo, CEO of the Foundation Fighting Blindness, says the organization is adapting its funding strategy, navigating regulatory challenges and accelerating the translation of academic discoveries into industry-led clinical development.

Biotech companies are pursuing diverse AI strategies beyond expensive custom data generation: foundation model fine-tuning, data-efficient computational methods and targeted proprietary datasets. In Vivo takes a look at some examples.

While big pharma pours billions into creating new anti-aging molecules, a Belgian startup has taken a different path: combining existing safe drugs with AI precision. The early results suggest it might be onto something revolutionary.

Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.